➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Baxter
McKesson
Johnson and Johnson
AstraZeneca

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 7,982,018

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,982,018
Title:Modified corticotropin releasing factor peptides and uses thereof
Abstract: The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically urocortin and urocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is covalently attached to a modified peptide or derivative, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide or derivative to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention preferably exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and preferably exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention.
Inventor(s): Ulich; Thomas R. (Flushing, NY), Estradier; Jean-Philippe (Montreal, CA), Thibaudeau; Karen (Rosemere, CA)
Assignee: Conjuchem, LLC (Culver City, CA)
Application Number:11/873,291
Patent Claims:see list of patent claims

Details for Patent 7,982,018

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Grifols Usa, Llc PLASBUMIN albumin (human) SOLUTION 101138 1 1994-09-26   Start Trial Conjuchem, LLC (Culver City, CA) 2026-10-16 search
Baxalta Us Inc. FLEXBUMIN albumin human INJECTION, SOLUTION 101452 1 2014-07-31   Start Trial Conjuchem, LLC (Culver City, CA) 2026-10-16 search
Csl Behring Ag ALBURX albumin (human) SOLUTION 102366 1 2009-01-06   Start Trial Conjuchem, LLC (Culver City, CA) 2026-10-16 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
Express Scripts
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.